Key result
ACE I/D polymorphism is not linked to digestive system cancer risk.
Why the study?
The association between angiotensin-converting enzyme (ACE) gene I/D polymorphisms and digestive system cancer risk was uncertain.
Does the ACE gene I/D polymorphism affect digestive system cancer risk?
Meta-Analysis (n=12,096)
Does the ACE gene I/D polymorphism affect digestive system cancer risk?
Odds Ratio: 0.93 (95% CI 0.75–1.16)
p-value: p=0.53
This meta-analysis found no significant association between the ACE D/I polymorphism and the risk of digestive system cancer.
Does not support ACE I/D testing for digestive cancer risk assessment; confirms lack of association in observational meta-analysis.
OBJECTIVE: To investigate the association between the gene polymorphisms of angiotensin-converting enzyme (ACE) and digestive system cancer risk. METHOD: A search was performed in Pubmed, Medline, ISI Web of Science and Chinese Biomedical (CBM) databases, covering all studies until Sep 1st, 2013. Statistical analysis was performed by using Revman5.2 and STATA 12.0. RESULTS: A total of 15 case-control studies comprising 2,390 digestive system cancer patients and 9,706 controls were identified. No significant association was found between the I/D polymorphism and digestive cancer risk (OR =0.93, 95%CI = (0.75, 1.16), P =0.53 for DD+DI vs. II). In the subgroup analysis by ethnicity and cancer type, no significant associations were found for the comparison of DD+DI vs. II. Results from other comparative genetic models also indicated a lack of associations between this polymorphism and digestive system cancer risks. CONCLUSIONS: This meta-analysis suggested that the ACE D/I polymorphism might not contribute to the risk of digestive system cancer.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) conducted a meta-analysis in Digestive system cancer (n=12,096). ACE gene I/D polymorphism (DD+DI genotypes) vs. II genotype was evaluated on Digestive system cancer risk (OR 0.93, 95% CI 0.75-1.16, p=0.53). The ACE I/D polymorphism (DD+DI vs. II) was not significantly associated with the risk of digestive system cancer (OR 0.93, p=0.53).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: